CONCLUSIONS
This feasibility study suggests that micronutrient abnormalities were
present in ninety percent of study patients. Subclinical micronutrient
deficiency can occur in patients who do not appear malnourished. Forty
percent of patients are receiving some form of micronutrient
supplementation. It is feasible to document toxicity and adverse events
on therapy. This is especially true if patients are enrolled in a
therapeutic clinical trial. The role of micronutrient supplementation to
assess benefit or harm is required. The role of micronutrients from a
cancer control perspective requires further basic and clinical
research28,29